The company expects an initial launch, if approved, to focus on FOP patients aged 12 and older. He said the company expects revenue from the potential product launch to begin more meaningfully in 2027. The company expects top-line results in the first quarter of 2027. Elsewhere in the rare liver pipeline, Mirum expects top-line results later in the quarter from the Phase III portion of the AZURE-1 study of brelovitug. About Mirum Pharmaceuticals (NASDAQ:MIRM)Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases.